

## Technology Advisory Interests Register

**Topic: Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Channa Hewamadduma	Expert	Direct – financial	<b>Biogen</b> <ul style="list-style-type: none"> <li>Sept/Oct 2022 - Teaching faculty of an educational meeting/ conference sponsored by Biogen</li> <li>May 2023- Speaker honoraria- ABN</li> <li>March 2023 Teaching faculty of an educational meeting/ conference sponsored by Roche and Biogen</li> <li>January/2024 - Adhoc advisory meeting - Biogen</li> </ul>	05/02/2024	It was agreed that Dr Hewamadduma's declaration would not prevent them from providing expert advice to the committee
			<b>Roche</b> <ul style="list-style-type: none"> <li>March 2023 Development of Risdiplam use Practical Guidance for clinicians' part I</li> <li>March 2023 Educational/speaker at conference</li> <li>April 2023 Advisory Board – reconnecting Disengaged SMA Adults to adult services</li> <li>July 2022 Development of Risdiplam use Practical</li> </ul>	25/01/2024	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Guidance for clinicians' part II</p> <ul style="list-style-type: none"> <li>October 2023 Interviewed by Sky News on SMA treatment access</li> </ul>		
		Indirect	<ul style="list-style-type: none"> <li>National Chief investigator in a Biogen associated clinical trial- in set up</li> <li>Chairing a Delphi panel on expert evidence gathering in managing gastro complication in Risdiplam- Medical writer is funded via Roche, though roche has no influence on content.</li> <li>Member of an evidence synthesis group on fertility related implications of risdiplam – author of a publication in ready to submit manuscript.</li> </ul>		
Dr Mariachristina Scoto	Expert	Direct – financial	<ul style="list-style-type: none"> <li>Involved as principal investigator in clinical trials from Roche and Biogen.</li> <li>Received consultancy honoraria for Scientific Advisory boards and teaching initiatives for Roche, Novartis and Biogen.</li> </ul>	11/12/2025 05/02/2024	It was agreed that Dr Scoto's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> <li>Involved as principal investigator in a Biogen sponsored trial.</li> </ul>	17/10/2025	
		Direct – non-financial	Co- principal investigator of the SMA REACH UK network, currently co-funded by Roche, Biogen and Novartis.	11/12/2025	
		Indirect	<ul style="list-style-type: none"> <li>Involved as principal investigator in clinical trials from Roche and Biogen.</li> <li>Co- principal investigator of the SMA REACH UK network, currently co-funded by Roche, Biogen and Novartis.</li> </ul>	05/02/2024	
Portia Thorman	Expert	Financial	SMA UK have received restricted funding for community projects. They have also completed patient prospective work for the companies involved with this appraisal	11/11/2025	It was agreed that Portia's declaration would not prevent them from providing expert advice to the committee